Base Editing and Prime Editing in Laboratory Animals
Overview
Authors
Affiliations
Genome editing by programmable RNA-dependent Cas endonucleases has revolutionised the field of genome engineering, achieving targeted genomic change at unprecedented efficiencies with considerable application in laboratory animal research. Despite its ease of use and wide application, there remain concerns about the precision of this technology and a number of unpredictable consequences have been reported, mostly resulting from the DNA doublestrand break (DSB) that conventional CRISPR editing induces. In order to improve editing precision, several iterations of the technology been developed over the years. Base editing is one of most successful developments, allowing for single base conversions but without the need for a DSB. Cytosine and adenine base editing are now established as reliable methods to achieve precise genome editing in animal research studies. Both cytosine and adenine base editors have been applied successfully to the editing of zygotes, resulting in the generation of animal models. Similarly, both base editors have achieved precise editing of point mutations in somatic cells, facilitating the development of gene therapy approaches. Despite rapid progress in optimising these tools, base editing can address only a subset of possible base conversions within a relatively narrow window and larger genomic manipulations are not possible. The recent development of prime editing, originally defined as a simple 'search and replace' editing tool, may help address these limitations and could widen the range of genome manipulations possible. Preliminary reports of prime editing in animals are being published, and this new technology may allow significant advancements for laboratory animal research.
Sato M, Inada E, Saitoh I, Morohoshi K, Nakamura S BioTech (Basel). 2024; 13(4).
PMID: 39584902 PMC: 11587059. DOI: 10.3390/biotech13040045.
PINE-TREE enables highly efficient genetic modification of human cell lines.
Frisch C, Kostes W, Galyon B, Whitman B, Tekel S, Standage-Beier K Mol Ther Nucleic Acids. 2023; 33:483-492.
PMID: 37588683 PMC: 10425837. DOI: 10.1016/j.omtn.2023.07.007.
CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis.
Shi Y, Zhao Y, Lu L, Gao Q, Yu D, Sun M Front Neurosci. 2023; 17:1223777.
PMID: 37483353 PMC: 10359984. DOI: 10.3389/fnins.2023.1223777.
Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System.
Wefers B, Wurst W, Kuhn R Methods Mol Biol. 2023; 2631:207-230.
PMID: 36995669 DOI: 10.1007/978-1-0716-2990-1_8.
Current advancement in the application of prime editing.
Huang Z, Liu G Front Bioeng Biotechnol. 2023; 11:1039315.
PMID: 36873365 PMC: 9978821. DOI: 10.3389/fbioe.2023.1039315.